Trial Profile

A phase 1 trial of VTx-002 for the treatment of ALS

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tamuzimod (Primary)
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions; Biomarker

Most Recent Events

18 Jun 2024 New trial record
17 Jun 2024 According to a UMC media release, first patient enrolled.
17 Jun 2024 According to a UMC media release, study results will be published in a peer-reviewed journal, contributing to the scientific community's understanding of ALS and its treatment.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com